Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study

OBJECTIVE: To evaluate the long‐term safety of rituximab in an observational cohort of patients with rheumatoid arthritis (RA) who had an inadequate response to ≥1 anti–tumor necrosis factor therapy in the US (SUNSTONE [Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an In...

Descripción completa

Detalles Bibliográficos
Autores principales: Winthrop, Kevin L., Saag, Kenneth, Cascino, Matthew D., Pei, Jinglan, John, Ani, Jahreis, Angelika, Haselkorn, Tmirah, Furst, Daniel E., Abdulky, M., Abeles, M., Adelglass, H., Ahmed, A., Alloway, J., Alper, J., Anand, A., Anderson, J., Arora, M., Askari, A., Baca, S., Bacha, D., Bagheri, S., Ballou, S., Bennett, R., Bidula, L., Blumstein, H., Bognar, M., Bohan, A., Boniske, C., Borofsky, M., Box, E., Braun, A., Brennan, T., Brent, L., Cabalar, I., Carteron, N., Chaudhary, K., Chauhan, A., Cima, M., Cochinwala, A., Cohen, H., Colburn, K., Conaway, D., Danning, C., Dao, K., Dean, J., Diab, I., Diegel, R., Ditzian‐Kadanoff, R., Dowd, J., Dugowson, C., Eggebeen, A., El‐Kadi, H., Feinberg, H., Feinman, M., Feinstein, J., Fischer, A., Foad, B., Fondal, M., Fraser, S., Fraser, A., Freeman, P., Garber, M., Goldstein, A., Golombek, S., Greenstein, N., Greenwald, M., Hakim, C., Halla, J., Hallegua, D., Han, K., Harris, B., Hauptman, H., Hirsh, J., Hoffman, M., Huntwork, J., Husni, M., Hyer, F., Hymowitz, R., Jones, R., Kanagasegar, S., Kappes, J., Keating, R., Kelly, G., Kim, J., King, C., Klashman, D., Knee, C., Kolba, K., Krick, G., Krug, H., Kumar, U., Lakhanpal, S., Lang, T., Lauter, S., Lawrence Ford, T., Lee, W., Lee, Y., Leisen, J., Levine, J., Lidman, R., Lipstate, J., Malinak, J., Marcus, R., Martin, D., Mehta, C., Melton, G., Metyas, S., Miller, K., Moidel, R., Moore, C., Mossell, J., Munoz, G., Murphy, F., Nami, A., Nascimento, J., Neal, N., Neiman, R., Neuwelt, C., Nguyen, P., Niemer, M., Oelke, K., Oza, M., Pachaidee, S., Patel, S., Pegram, S., Penmetcha, M., Perkins, J., Perl, A., Peterson, L., Pittsley, R., Portnoff, K., Rahmani, D., Raja, N., Ratnoff, W., Rezaian, M., Rhea, C., Rice, D., Ridley, D., Rivadeneira, A., Rizzo, W., Roane, G., Rocca, P., Rosen, M., Saikali, W., Saitta, M., Sankoorikal, A., Saway, P., Schneider, P., Schwartzman, S., Scoville, C., Shergy, W., Shiel, W, Shurmur, R., Sikes, D., Singhal, A., Snyder, A., Songcharoen, S., Sosenko, M., Soto Raices, O., Stahl, N., Stark, K., Strachan, M., Stupi, A., Sullivan, N., Sylvester, R., Tabechian, D., Tagoe, C., Taylor, P., Thakker, S., Thakor, M., Thakur, N., Tidmore, W., Toth, M., Trostle, D., Udell, J., Van de Stouwe, M., Venuturupalli, R., Weiss, D., Weselman, K., Winn, D., Yung, C., Zable, E., Zamiri, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6806017/
https://www.ncbi.nlm.nih.gov/pubmed/30295434
http://dx.doi.org/10.1002/acr.23781
_version_ 1783461530328629248
author Winthrop, Kevin L.
Saag, Kenneth
Cascino, Matthew D.
Pei, Jinglan
John, Ani
Jahreis, Angelika
Haselkorn, Tmirah
Furst, Daniel E.
Abdulky, M.
Abeles, M.
Adelglass, H.
Ahmed, A.
Alloway, J.
Alper, J.
Anand, A.
Anderson, J.
Arora, M.
Askari, A.
Baca, S.
Bacha, D.
Bagheri, S.
Ballou, S.
Bennett, R.
Bidula, L.
Blumstein, H.
Bognar, M.
Bohan, A.
Boniske, C.
Borofsky, M.
Box, E.
Braun, A.
Brennan, T.
Brent, L.
Cabalar, I.
Carteron, N.
Chaudhary, K.
Chauhan, A.
Cima, M.
Cochinwala, A.
Cohen, H.
Colburn, K.
Conaway, D.
Danning, C.
Dao, K.
Dean, J.
Diab, I.
Diegel, R.
Ditzian‐Kadanoff, R.
Dowd, J.
Dugowson, C.
Eggebeen, A.
El‐Kadi, H.
Feinberg, H.
Feinman, M.
Feinstein, J.
Fischer, A.
Foad, B.
Fondal, M.
Fraser, S.
Fraser, A.
Freeman, P.
Garber, M.
Goldstein, A.
Golombek, S.
Greenstein, N.
Greenwald, M.
Hakim, C.
Halla, J.
Hallegua, D.
Han, K.
Harris, B.
Hauptman, H.
Hirsh, J.
Hoffman, M.
Huntwork, J.
Husni, M.
Hyer, F.
Hymowitz, R.
Jones, R.
Kanagasegar, S.
Kappes, J.
Keating, R.
Kelly, G.
Kim, J.
King, C.
Klashman, D.
Knee, C.
Kolba, K.
Krick, G.
Krug, H.
Kumar, U.
Lakhanpal, S.
Lang, T.
Lauter, S.
Lawrence Ford, T.
Lee, W.
Lee, Y.
Leisen, J.
Levine, J.
Lidman, R.
Lipstate, J.
Malinak, J.
Marcus, R.
Martin, D.
Mehta, C.
Melton, G.
Metyas, S.
Miller, K.
Moidel, R.
Moore, C.
Mossell, J.
Munoz, G.
Murphy, F.
Nami, A.
Nascimento, J.
Neal, N.
Neiman, R.
Neuwelt, C.
Nguyen, P.
Niemer, M.
Oelke, K.
Oza, M.
Pachaidee, S.
Patel, S.
Pegram, S.
Penmetcha, M.
Perkins, J.
Perl, A.
Peterson, L.
Pittsley, R.
Portnoff, K.
Rahmani, D.
Raja, N.
Ratnoff, W.
Rezaian, M.
Rhea, C.
Rice, D.
Ridley, D.
Rivadeneira, A.
Rizzo, W.
Roane, G.
Rocca, P.
Rosen, M.
Saikali, W.
Saitta, M.
Sankoorikal, A.
Saway, P.
Schneider, P.
Schwartzman, S.
Scoville, C.
Shergy, W.
Shiel, W
Shurmur, R.
Sikes, D.
Singhal, A.
Snyder, A.
Songcharoen, S.
Sosenko, M.
Soto Raices, O.
Stahl, N.
Stark, K.
Strachan, M.
Stupi, A.
Sullivan, N.
Sylvester, R.
Tabechian, D.
Tagoe, C.
Taylor, P.
Thakker, S.
Thakor, M.
Thakur, N.
Tidmore, W.
Toth, M.
Trostle, D.
Udell, J.
Van de Stouwe, M.
Venuturupalli, R.
Weiss, D.
Weselman, K.
Winn, D.
Yung, C.
Zable, E.
Zamiri, B.
author_facet Winthrop, Kevin L.
Saag, Kenneth
Cascino, Matthew D.
Pei, Jinglan
John, Ani
Jahreis, Angelika
Haselkorn, Tmirah
Furst, Daniel E.
Abdulky, M.
Abeles, M.
Adelglass, H.
Ahmed, A.
Alloway, J.
Alper, J.
Anand, A.
Anderson, J.
Arora, M.
Askari, A.
Baca, S.
Bacha, D.
Bagheri, S.
Ballou, S.
Bennett, R.
Bidula, L.
Blumstein, H.
Bognar, M.
Bohan, A.
Boniske, C.
Borofsky, M.
Box, E.
Braun, A.
Brennan, T.
Brent, L.
Cabalar, I.
Carteron, N.
Chaudhary, K.
Chauhan, A.
Cima, M.
Cochinwala, A.
Cohen, H.
Colburn, K.
Conaway, D.
Danning, C.
Dao, K.
Dean, J.
Diab, I.
Diegel, R.
Ditzian‐Kadanoff, R.
Dowd, J.
Dugowson, C.
Eggebeen, A.
El‐Kadi, H.
Feinberg, H.
Feinman, M.
Feinstein, J.
Fischer, A.
Foad, B.
Fondal, M.
Fraser, S.
Fraser, A.
Freeman, P.
Garber, M.
Goldstein, A.
Golombek, S.
Greenstein, N.
Greenwald, M.
Hakim, C.
Halla, J.
Hallegua, D.
Han, K.
Harris, B.
Hauptman, H.
Hirsh, J.
Hoffman, M.
Huntwork, J.
Husni, M.
Hyer, F.
Hymowitz, R.
Jones, R.
Kanagasegar, S.
Kappes, J.
Keating, R.
Kelly, G.
Kim, J.
King, C.
Klashman, D.
Knee, C.
Kolba, K.
Krick, G.
Krug, H.
Kumar, U.
Lakhanpal, S.
Lang, T.
Lauter, S.
Lawrence Ford, T.
Lee, W.
Lee, Y.
Leisen, J.
Levine, J.
Lidman, R.
Lipstate, J.
Malinak, J.
Marcus, R.
Martin, D.
Mehta, C.
Melton, G.
Metyas, S.
Miller, K.
Moidel, R.
Moore, C.
Mossell, J.
Munoz, G.
Murphy, F.
Nami, A.
Nascimento, J.
Neal, N.
Neiman, R.
Neuwelt, C.
Nguyen, P.
Niemer, M.
Oelke, K.
Oza, M.
Pachaidee, S.
Patel, S.
Pegram, S.
Penmetcha, M.
Perkins, J.
Perl, A.
Peterson, L.
Pittsley, R.
Portnoff, K.
Rahmani, D.
Raja, N.
Ratnoff, W.
Rezaian, M.
Rhea, C.
Rice, D.
Ridley, D.
Rivadeneira, A.
Rizzo, W.
Roane, G.
Rocca, P.
Rosen, M.
Saikali, W.
Saitta, M.
Sankoorikal, A.
Saway, P.
Schneider, P.
Schwartzman, S.
Scoville, C.
Shergy, W.
Shiel, W
Shurmur, R.
Sikes, D.
Singhal, A.
Snyder, A.
Songcharoen, S.
Sosenko, M.
Soto Raices, O.
Stahl, N.
Stark, K.
Strachan, M.
Stupi, A.
Sullivan, N.
Sylvester, R.
Tabechian, D.
Tagoe, C.
Taylor, P.
Thakker, S.
Thakor, M.
Thakur, N.
Tidmore, W.
Toth, M.
Trostle, D.
Udell, J.
Van de Stouwe, M.
Venuturupalli, R.
Weiss, D.
Weselman, K.
Winn, D.
Yung, C.
Zable, E.
Zamiri, B.
author_sort Winthrop, Kevin L.
collection PubMed
description OBJECTIVE: To evaluate the long‐term safety of rituximab in an observational cohort of patients with rheumatoid arthritis (RA) who had an inadequate response to ≥1 anti–tumor necrosis factor therapy in the US (SUNSTONE [Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti‐TNF Therapy] registry). METHODS: In this prospective, observational cohort study, patients received rituximab according to their physician's standard practice and were evaluated at standard‐of‐care follow‐up visits at least every 6 months. The primary outcome was the incidence of protocol‐defined significant infections. Secondary outcomes included serious adverse events potentially associated with rituximab, cardiovascular or thrombotic events, seizures, deaths, and pregnancies. Post hoc analyses assessed outcomes by concomitant medication use. RESULTS: Overall, 989 patients (safety‐evaluable population) received ≥1 dose of rituximab, with a total follow‐up of 3,844 patient‐years (mean duration 3.9 years). In total, 341 significant infections occurred in 197 patients (19.9%). The incidence rates (95% confidence intervals [95% CIs]) for significant infections, cardiovascular or thrombotic events, and seizures were 8.87 (95% CI 7.98–9.86), 1.95 (95% CI 1.56–2.45), and 0.18 (95% CI 0.09–0.38) per 100 patient‐years, respectively. The incidence of significant infections did not increase with time or with cumulative rituximab exposure. During the study, 64 patients died (crude mortality rate 1.66 per 100 patient‐years [95% CI 1.30–2.13]). The most common causes of death were infections (n = 19), malignancy (n = 14), and cardiovascular events (n = 13). Eight pregnancies were reported in 7 patients. CONCLUSION: In patients with RA treated with rituximab for up to 5 years, the rates of significant infections were stable over time and higher in patients who received long‐term systemic steroid treatment.
format Online
Article
Text
id pubmed-6806017
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-68060172019-10-28 Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study Winthrop, Kevin L. Saag, Kenneth Cascino, Matthew D. Pei, Jinglan John, Ani Jahreis, Angelika Haselkorn, Tmirah Furst, Daniel E. Abdulky, M. Abeles, M. Adelglass, H. Ahmed, A. Alloway, J. Alper, J. Anand, A. Anderson, J. Arora, M. Askari, A. Baca, S. Bacha, D. Bagheri, S. Ballou, S. Bennett, R. Bidula, L. Blumstein, H. Bognar, M. Bohan, A. Boniske, C. Borofsky, M. Box, E. Braun, A. Brennan, T. Brent, L. Cabalar, I. Carteron, N. Chaudhary, K. Chauhan, A. Cima, M. Cochinwala, A. Cohen, H. Colburn, K. Conaway, D. Danning, C. Dao, K. Dean, J. Diab, I. Diegel, R. Ditzian‐Kadanoff, R. Dowd, J. Dugowson, C. Eggebeen, A. El‐Kadi, H. Feinberg, H. Feinman, M. Feinstein, J. Fischer, A. Foad, B. Fondal, M. Fraser, S. Fraser, A. Freeman, P. Garber, M. Goldstein, A. Golombek, S. Greenstein, N. Greenwald, M. Hakim, C. Halla, J. Hallegua, D. Han, K. Harris, B. Hauptman, H. Hirsh, J. Hoffman, M. Huntwork, J. Husni, M. Hyer, F. Hymowitz, R. Jones, R. Kanagasegar, S. Kappes, J. Keating, R. Kelly, G. Kim, J. King, C. Klashman, D. Knee, C. Kolba, K. Krick, G. Krug, H. Kumar, U. Lakhanpal, S. Lang, T. Lauter, S. Lawrence Ford, T. Lee, W. Lee, Y. Leisen, J. Levine, J. Lidman, R. Lipstate, J. Malinak, J. Marcus, R. Martin, D. Mehta, C. Melton, G. Metyas, S. Miller, K. Moidel, R. Moore, C. Mossell, J. Munoz, G. Murphy, F. Nami, A. Nascimento, J. Neal, N. Neiman, R. Neuwelt, C. Nguyen, P. Niemer, M. Oelke, K. Oza, M. Pachaidee, S. Patel, S. Pegram, S. Penmetcha, M. Perkins, J. Perl, A. Peterson, L. Pittsley, R. Portnoff, K. Rahmani, D. Raja, N. Ratnoff, W. Rezaian, M. Rhea, C. Rice, D. Ridley, D. Rivadeneira, A. Rizzo, W. Roane, G. Rocca, P. Rosen, M. Saikali, W. Saitta, M. Sankoorikal, A. Saway, P. Schneider, P. Schwartzman, S. Scoville, C. Shergy, W. Shiel, W Shurmur, R. Sikes, D. Singhal, A. Snyder, A. Songcharoen, S. Sosenko, M. Soto Raices, O. Stahl, N. Stark, K. Strachan, M. Stupi, A. Sullivan, N. Sylvester, R. Tabechian, D. Tagoe, C. Taylor, P. Thakker, S. Thakor, M. Thakur, N. Tidmore, W. Toth, M. Trostle, D. Udell, J. Van de Stouwe, M. Venuturupalli, R. Weiss, D. Weselman, K. Winn, D. Yung, C. Zable, E. Zamiri, B. Arthritis Care Res (Hoboken) Rheumatoid Arthritis OBJECTIVE: To evaluate the long‐term safety of rituximab in an observational cohort of patients with rheumatoid arthritis (RA) who had an inadequate response to ≥1 anti–tumor necrosis factor therapy in the US (SUNSTONE [Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti‐TNF Therapy] registry). METHODS: In this prospective, observational cohort study, patients received rituximab according to their physician's standard practice and were evaluated at standard‐of‐care follow‐up visits at least every 6 months. The primary outcome was the incidence of protocol‐defined significant infections. Secondary outcomes included serious adverse events potentially associated with rituximab, cardiovascular or thrombotic events, seizures, deaths, and pregnancies. Post hoc analyses assessed outcomes by concomitant medication use. RESULTS: Overall, 989 patients (safety‐evaluable population) received ≥1 dose of rituximab, with a total follow‐up of 3,844 patient‐years (mean duration 3.9 years). In total, 341 significant infections occurred in 197 patients (19.9%). The incidence rates (95% confidence intervals [95% CIs]) for significant infections, cardiovascular or thrombotic events, and seizures were 8.87 (95% CI 7.98–9.86), 1.95 (95% CI 1.56–2.45), and 0.18 (95% CI 0.09–0.38) per 100 patient‐years, respectively. The incidence of significant infections did not increase with time or with cumulative rituximab exposure. During the study, 64 patients died (crude mortality rate 1.66 per 100 patient‐years [95% CI 1.30–2.13]). The most common causes of death were infections (n = 19), malignancy (n = 14), and cardiovascular events (n = 13). Eight pregnancies were reported in 7 patients. CONCLUSION: In patients with RA treated with rituximab for up to 5 years, the rates of significant infections were stable over time and higher in patients who received long‐term systemic steroid treatment. John Wiley and Sons Inc. 2019-07-04 2019-08 /pmc/articles/PMC6806017/ /pubmed/30295434 http://dx.doi.org/10.1002/acr.23781 Text en © 2018, The Authors. Arthritis Care & Research published by Wiley Periodicals, Inc. on behalf of American College of Rheumatology. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Rheumatoid Arthritis
Winthrop, Kevin L.
Saag, Kenneth
Cascino, Matthew D.
Pei, Jinglan
John, Ani
Jahreis, Angelika
Haselkorn, Tmirah
Furst, Daniel E.
Abdulky, M.
Abeles, M.
Adelglass, H.
Ahmed, A.
Alloway, J.
Alper, J.
Anand, A.
Anderson, J.
Arora, M.
Askari, A.
Baca, S.
Bacha, D.
Bagheri, S.
Ballou, S.
Bennett, R.
Bidula, L.
Blumstein, H.
Bognar, M.
Bohan, A.
Boniske, C.
Borofsky, M.
Box, E.
Braun, A.
Brennan, T.
Brent, L.
Cabalar, I.
Carteron, N.
Chaudhary, K.
Chauhan, A.
Cima, M.
Cochinwala, A.
Cohen, H.
Colburn, K.
Conaway, D.
Danning, C.
Dao, K.
Dean, J.
Diab, I.
Diegel, R.
Ditzian‐Kadanoff, R.
Dowd, J.
Dugowson, C.
Eggebeen, A.
El‐Kadi, H.
Feinberg, H.
Feinman, M.
Feinstein, J.
Fischer, A.
Foad, B.
Fondal, M.
Fraser, S.
Fraser, A.
Freeman, P.
Garber, M.
Goldstein, A.
Golombek, S.
Greenstein, N.
Greenwald, M.
Hakim, C.
Halla, J.
Hallegua, D.
Han, K.
Harris, B.
Hauptman, H.
Hirsh, J.
Hoffman, M.
Huntwork, J.
Husni, M.
Hyer, F.
Hymowitz, R.
Jones, R.
Kanagasegar, S.
Kappes, J.
Keating, R.
Kelly, G.
Kim, J.
King, C.
Klashman, D.
Knee, C.
Kolba, K.
Krick, G.
Krug, H.
Kumar, U.
Lakhanpal, S.
Lang, T.
Lauter, S.
Lawrence Ford, T.
Lee, W.
Lee, Y.
Leisen, J.
Levine, J.
Lidman, R.
Lipstate, J.
Malinak, J.
Marcus, R.
Martin, D.
Mehta, C.
Melton, G.
Metyas, S.
Miller, K.
Moidel, R.
Moore, C.
Mossell, J.
Munoz, G.
Murphy, F.
Nami, A.
Nascimento, J.
Neal, N.
Neiman, R.
Neuwelt, C.
Nguyen, P.
Niemer, M.
Oelke, K.
Oza, M.
Pachaidee, S.
Patel, S.
Pegram, S.
Penmetcha, M.
Perkins, J.
Perl, A.
Peterson, L.
Pittsley, R.
Portnoff, K.
Rahmani, D.
Raja, N.
Ratnoff, W.
Rezaian, M.
Rhea, C.
Rice, D.
Ridley, D.
Rivadeneira, A.
Rizzo, W.
Roane, G.
Rocca, P.
Rosen, M.
Saikali, W.
Saitta, M.
Sankoorikal, A.
Saway, P.
Schneider, P.
Schwartzman, S.
Scoville, C.
Shergy, W.
Shiel, W
Shurmur, R.
Sikes, D.
Singhal, A.
Snyder, A.
Songcharoen, S.
Sosenko, M.
Soto Raices, O.
Stahl, N.
Stark, K.
Strachan, M.
Stupi, A.
Sullivan, N.
Sylvester, R.
Tabechian, D.
Tagoe, C.
Taylor, P.
Thakker, S.
Thakor, M.
Thakur, N.
Tidmore, W.
Toth, M.
Trostle, D.
Udell, J.
Van de Stouwe, M.
Venuturupalli, R.
Weiss, D.
Weselman, K.
Winn, D.
Yung, C.
Zable, E.
Zamiri, B.
Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study
title Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study
title_full Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study
title_fullStr Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study
title_full_unstemmed Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study
title_short Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study
title_sort long‐term safety of rituximab in patients with rheumatoid arthritis: results of a five‐year observational study
topic Rheumatoid Arthritis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6806017/
https://www.ncbi.nlm.nih.gov/pubmed/30295434
http://dx.doi.org/10.1002/acr.23781
work_keys_str_mv AT winthropkevinl longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT saagkenneth longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT cascinomatthewd longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT peijinglan longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT johnani longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT jahreisangelika longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT haselkorntmirah longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT furstdaniele longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT abdulkym longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT abelesm longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT adelglassh longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT ahmeda longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT allowayj longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT alperj longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT ananda longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT andersonj longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT aroram longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT askaria longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT bacas longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT bachad longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT bagheris longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT ballous longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT bennettr longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT bidulal longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT blumsteinh longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT bognarm longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT bohana longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT boniskec longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT borofskym longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT boxe longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT brauna longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT brennant longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT brentl longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT cabalari longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT carteronn longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT chaudharyk longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT chauhana longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT cimam longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT cochinwalaa longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT cohenh longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT colburnk longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT conawayd longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT danningc longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT daok longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT deanj longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT diabi longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT diegelr longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT ditziankadanoffr longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT dowdj longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT dugowsonc longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT eggebeena longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT elkadih longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT feinbergh longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT feinmanm longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT feinsteinj longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT fischera longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT foadb longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT fondalm longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT frasers longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT frasera longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT freemanp longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT garberm longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT goldsteina longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT golombeks longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT greensteinn longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT greenwaldm longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT hakimc longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT hallaj longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT halleguad longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT hank longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT harrisb longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT hauptmanh longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT hirshj longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT hoffmanm longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT huntworkj longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT husnim longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT hyerf longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT hymowitzr longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT jonesr longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT kanagasegars longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT kappesj longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT keatingr longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT kellyg longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT kimj longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT kingc longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT klashmand longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT kneec longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT kolbak longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT krickg longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT krugh longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT kumaru longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT lakhanpals longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT langt longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT lauters longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT lawrencefordt longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT leew longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT leey longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT leisenj longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT levinej longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT lidmanr longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT lipstatej longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT malinakj longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT marcusr longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT martind longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT mehtac longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT meltong longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT metyass longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT millerk longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT moidelr longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT moorec longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT mossellj longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT munozg longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT murphyf longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT namia longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT nascimentoj longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT nealn longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT neimanr longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT neuweltc longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT nguyenp longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT niemerm longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT oelkek longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT ozam longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT pachaidees longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT patels longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT pegrams longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT penmetcham longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT perkinsj longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT perla longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT petersonl longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT pittsleyr longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT portnoffk longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT rahmanid longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT rajan longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT ratnoffw longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT rezaianm longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT rheac longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT riced longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT ridleyd longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT rivadeneiraa longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT rizzow longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT roaneg longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT roccap longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT rosenm longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT saikaliw longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT saittam longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT sankoorikala longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT sawayp longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT schneiderp longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT schwartzmans longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT scovillec longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT shergyw longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT shielw longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT shurmurr longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT sikesd longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT singhala longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT snydera longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT songcharoens longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT sosenkom longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT sotoraiceso longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT stahln longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT starkk longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT strachanm longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT stupia longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT sullivann longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT sylvesterr longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT tabechiand longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT tagoec longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT taylorp longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT thakkers longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT thakorm longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT thakurn longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT tidmorew longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT tothm longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT trostled longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT udellj longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT vandestouwem longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT venuturupallir longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT weissd longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT weselmank longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT winnd longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT yungc longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT zablee longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy
AT zamirib longtermsafetyofrituximabinpatientswithrheumatoidarthritisresultsofafiveyearobservationalstudy

Ejemplares similares